Drug Trial Radar · NCT06468358
A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
194
Planned (sponsor's estimate)
Start
Jun 19, 2024
Primary completion
Dec 30, 2026
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- L & L Bio Co., Ltd., Ningbo, ChinaIndustry
- Sponsor type
- Industry
- Collaborators
- Shanghai East Hospital
- First posted
- Jun 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase Ib/II, open, dose-escalation and expansion study of an anti-PD1/TIM3 bispecific antibody,LB1410 in combination with an anti-Claudin18.2/IL-10 fusion protein, LB4330 in patients with advanced or metastatic solid tumors.
Conditions
- Solid Tumor
Interventions
LB1410Drug
anti-PD-1/TIM3 bispecific antibody
LB4330Drug
anti-claudin18.2/IL-10 fusion protein
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability (Adverse Event reported per NCI-CTCAE v5.0)Time frame: up to 60 days following last dose
- Incidence and severity of serious adverse events (SAEs) and other special interest (immune-related AEs)Time frame: up to 60 days following last dose
- Incidence of Dose limiting toxicity (DLT)Time frame: At the end of Cycle 1 (each cycle is 28 days)
- Maximum tolerance toxicity (MTD) and recommended dose for Phase II (RP2D) definitionTime frame: up to 1 year
- Overall response rate (ORR)Time frame: From first participant until last participant assessment, an average of 8 months
- Disease control rate (DCR)Time frame: From first participant until last participant assessment, an average of 8 months
- Duration of overall Response (DoR) by RECIST version 1.1Time frame: From first participant until last participant assessment, an average of 8 months
- Progression Free Survival (PFS) by RECIST version 1.1Time frame: From first participant until last participant assessment, an average of 8 months
- DDCTime frame: From first participant until last participant assessment, an average of 8 months
- Overall Survival (OS) durationTime frame: From first participant until last participant assessment, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.